The war on CBD stems back from the American history on marijuana. When the substance under the controlled act of 1970 was put into effect, cannabis was outlawed and the President declared it as a hard substance without medicinal value.
It has not been easy since then for the hemp and cannabis-related industries. The York was exerted more when the Drug Enforcement Administration(DEA) declared the cannabidiol related products as schedule 1. The move caught many traders and medical practitioners by surprise.
For a long time, CBD has been medically vital for many reasons arising from its effects including:
- Pain relievers.
- Treating bowel inflammatory issues.
- Curbing stress, anxiety, and depression.
- Preventing cardiovascular conditions.
- Reducing the effects of cancer treatment effects like chemotherapy.
- Reducing acne
What Is A Schedule 1 Drug?
Classifying CBD Schedule 1 meant a lot in the hemp industry. A schedule 1 drug is a highly restrictive drug in the US. The national government placed stringent rules on the consumption of these drugs. The reasons for classifying any drug as schedule 1 are attached closely to the side effects.
This classification implied that:
- CBD had no medical value.
- The cannabidiol is likely to influence the user into addiction.
- CBD has THC compound which leads users to substance abuse.
Any drug with a high content of THC, tetrahydrocannabinol, is classified as a hard drug. This is a similar category of the heroine, and coke.
Contest against CBD Schedule 1 Classification
With all the fuss about CBD schedule issues, some companies moved to court to protest against it. These companies among others include Centuria Natural Foods, and Hemp Industries and Association (HIA). They fought hard on the basis of the THC content in the CBD and the medical value it has.
The duo, also demonstrated the side effects of CBD oil, for instance, it has a low potential to abuse. Furthermore, some states in the US including Irvine and Bakersfield, accept the medical use of marijuana and cannabis related-products.
Though they are used under strict state laws, it is an indication of how valuable the CBD is to the public. Jeffrey Zucker criticized the move by DEA as an inconsiderate step to classify the CBD schedule 1. He cited how the, by all means, gets into that bracket with its low percentage of the psychoactive compound.
A drug getting into the Schedule 1 attracts heavy penalties under the national and state laws.
What kept the war under control was the protection CBD products enjoy under the 2014 Farm Bill. It was the willpower law that propelled the concerned parties to keep hanging in there. The law allows them to prove legal processing in their production.
Through the hemp policy, the stakeholders moved in with full force based on research-based benefits and justifying the non-addictive nature of CBD schedule 1.
Relief at last
With too much nagging and pressure from the relevant stakeholders, DEA bows down to the evidence-based arguments. That gave a sigh of relief to the CBD-related producers and the hope to have a robust engagement into more CBD cannabidiol products.
One of the CBD products was lowered from the CBD schedule 1 to schedule 5. Epidiolex has been a long-standing relieve to the rare kind of epilepsy that affects children. This will be the first CBD product that is non-synthetic to get to the legal public domain after a long push and pull.
Epidiolex was legalized by the DEA after thorough scrutiny and research on its possible effects to addiction and the THC content. For any drug to qualify out of the CBD schedule 1, both DEA and Food and Drugs Administration(FDA) have to ascertain their safety to the consumers.
The content of THC in the Epidiolex is below 0.1%. That means the drug can hardly cause euphoric effects to the users. With “high” effects not in the offing, the drug sneaks through the DEA net. Therefore, most users and especially the children with epileptic conditions, sand to benefit a great deal.
The implications of the CBD schedule 1 reversal
The move by DEA to reclassify the CBD to schedule 5, has a lot of impacts both in the world of medics, production, and supply of the CBD products.
However, it does not mean that the CBD product is now legal. The entire products under the schedules 1 to schedule 5 are still illegal. The only difference is that the CBD schedule 1 does not face a legal force like the CBD schedule 5. The products in schedule 5 are safe to the consumers as long as they are taken under guidance.
Let’s narrow down the effects of the DEA approval to the Epidiolex:
- The Epidiolex has low risk to influence addiction which was the fear and the speculation of the government, with the fact at hand, the expansion of its use will be more and more open into the public.
- There shall be an open market to the investors and the producers.
- More investment in research on how viable the CBD can be more beneficial in other medical conditions within the low THC environment.
- The able pharmaceutical companies will spend midnight oil in the labs to generate more CBD-related products for diverse use in medicine.
Well, besides the epileptic children. Epidiolex is still vital to other conditions that the doctors will deem consistent with its treatment. Therefore, the availability of these drugs will no longer be under hospital control but will be available in more cannabis stores in the US.
Many employees had to down their tools for fear of the drug tests. With the trend in the cannabis research, there is hope that, in the near future, many other CBD schedule 1 products will be sent back the fold of safe use.
- james Munitello, cannot express his joy better, the CEO of Leaf Logix expresses gratitude to the war fought so far. He deeply believes it is the new beginning into the CBD schedule 1 freedom.
- it is expected to be a robust business in the US for the hemp industries already showing a positive impact in their market shares.